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Background: The vitreous humor is a transparent, gelatinous mass whose main constituent is water. It plays an
important role in providing metabolic nutrient requirements of the lens, coordinating eye growth and providing
support to the retina. It is in close proximity to the retina and reflects many of the changes occurring in this tissue.
The biochemical changes occurring in the vitreous could provide a better understanding about the
pathophysiological processes that occur in vitreoretinopathy. In this study, we investigated the proteome of normal
human vitreous humor using high resolution Fourier transform mass spectrometry.
Results: The vitreous humor was subjected to multiple fractionation techniques followed by LC-MS/MS analysis. We
identified 1,205 proteins, 682 of which have not been described previously in the vitreous humor. Most proteins
were localized to the extracellular space (24%), cytoplasm (20%) or plasma membrane (14%). Classification based on
molecular function showed that 27% had catalytic activity, 10% structural activity, 10% binding activity, 4% cell and
4% transporter activity. Categorization for biological processes showed 28% participate in metabolism, 20% in cell
communication and 13% in cell growth. The data have been deposited to the ProteomeXchange with identifier
PXD000957.
Conclusion: This large catalog of vitreous proteins should facilitate biomedical research into pathological
conditions of the eye including diabetic retinopathy, retinal detachment and cataract.
Keywords: Retina, SCX chromatography, OFFGEL electrophoresis, Proteome discoverer, Secreted proteins,
Protein biomarkers, Body fluid proteomicsBackground
The vitreous is a highly hydrated gelatinous mass that fills
the space between the lens and the retina. The vitreous is
adherent to the retina diffusely though the adhesion is
strongest at the anterior border of retina, the macula, the
optic nerve head, over lattice degenerations and areas of
scars. The major function of the vitreous is to allow light
to reach the retina and maintain the shape of the eyeball.
The formation of vitreous occurs in two phases. Primary
vitreous is formed by the third or fourth week of gestation,
when the neural ectoderm separates from the surface
ectoderm. The space between the two is the future* Correspondence: krishna@viio.org
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unless otherwise stated.vitreous cavity. This space is bridged by fibrillar material
which is thought to be collagenous in nature. By the time
the fetus reaches the 10 mm stage, mesodermal cells enter
the vitreous space via the fetal fissure and develop into
hyaloid vessels which branch throughout the vitreous
cavity [1]. In the adventitia surrounding the vessels, there
are mononuclear phagocytes and fibroblasts which are
thought to later differentiate into hyalocytes. This cellular
vitreous is the primary vitreous. Acellular structures begin
to appear by end of the sixth week of gestation between
the retina and the hyaloid vasculature. This secondary
vitreous is essentially extracellular matrix consisting
primarily of type 2 collagen [2]. With the development
of the secondary vitreous, the hyaloid vascular system
regresses. Hyalocytes appear to be the most important
cells and after birth, there is no new migration of these
cells into the vitreous cortex. Thus, with an increase in
globe size and vitreous cortex surface area, there is a
decrease in the density of hyalocytes. Since the vitreousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and surrounding tissues [3], some of the proteins in
vitreous humor could be contributed by these surround-
ing tissues. Its viscosity is two to four times greater than
water, which gives it a gelatinous consistency [4]. The
human vitreous is composed of a complex network of
cross-linked collagen fibres of types II, V, IX and XI of
which type II is the most abundant. Non-collagenous
structural proteins are less abundant as compared to
collagen fibrils. Hyaluronic acid, a glycosaminoglycan is
also found in abundance in the vitreous [5,6]. A significant
amount of prealbumin and transferrin in the vitreous has
also been reported [7-9]. Of the soluble proteins that con-
stitute the vitreous, sialic acid containing glycoproteins
constitute the largest fraction [10].
It is well understood that the changes occurring in the
retina are closely linked to biochemical changes occurring
in the vitreous humor [11]. Vitreous humor does not have
any blood vessels but is nourished by vessels of the retina
and the ciliary body. As the vitreous can be easily obtained
during vitrectomy surgery, studying the changes occurring
in the vitreous could provide valuable information about
pathological changes occurring in the retina in disorders
of the eye. Many researchers have studied the proteins of
the normal vitreous using different techniques and some
of them have also catalogued various proteins [12-16].
Nakanishi et al., have catalogued 51 proteins in the vitre-
ous by Matrix assisted laser desorption ionization-time of
flight (MALDI-TOF) mass spectrometry [12]. Kim et al.
employed immunoaffinity depletion followed by nano-
liquid chromatography-Matrix assisted laser desorption
ionization (LC-MALDI-MS/MS) resulting in the identifi-
cation of 346 proteins from non-diabetic controls [13]. In
a subsequent study, Gao et al. identified 252 proteins from
the vitreous employing sodium dodecyl sulphate polya-
cylamide gel electrophoresis (SDS-PAGE) analyzed by
LC-MS/MS [14]. Aretz et al have identified 1,111 distinct
proteins by employing different protein prefractionation
strategies such as liquid phase isoelectric focussing, 1D
SDS gel electrophoresis and a combination of both [16].
Here, we identified 1,205 proteins of which 682 proteins
have been detected in the vitreous humor for the first
time. A comprehensive proteomic profiling of normal
vitreous would serve as an invaluable template for future
studies that focus on protein dynamics in vitreous in
pathological conditions.
Results and discussion
Proteomic analysis of the vitreous humor was carried
out by depleting the samples of abundant proteins and
subjecting it to multiple fractionation techniques, such
as In-gel digestion, SCX and OFFGEL fractionation.
LC-MS/MS analyses of the different fractions were carried
out on an LTQ-Orbitrap Velos (Thermo Electron, Bremen,Germany) mass spectrometer. The corresponding MS
data were searched using the search algorithms Mascot,
SEQUEST and X! Tandem against NCBI RefSeq 59 human
protein database containing 36,211 sequences with known
contaminants (Figure 1). This resulted in the identification
of 7,642 peptides from 1,205 proteins. A complete list of
proteins identified in vitreous is provided in Additional
file 1: Table S1 along with their known sub cellular
localization, molecular function, biological process, do-
mains/motifs, number of peptides and sequence coverage.
Protein identifications include 41 proteins designated as
‘missing proteins’ by c-HPP and these are highlighted in
Additional file 1: Table S1. A list of peptides identified
from this study from all three searches is provided in
Additional file 2: Table S2. When compared to previous
reports, 682 proteins out of 1,205 were found to be
uniquely identified in this study. A partial list of these
proteins is provided in Table 1. The description of 3 novel
proteins identified in this study and four previously re-
ported proteins is provided in following sections.
Proteomic analysis of the vitreous has been carried out
by many groups using different techniques as summarized
in Table 2. Some of the proteins not identified in the
present study in comparison to previous studies may be
due to differences in sample preparation methods or mass
spectrometry platforms employed. Since obtaining normal
vitreous from healthy individuals is not a possibility, clin-
ically normal appearing vitreous samples from patients
undergoing vitrectomy surgery for macular hole or trau-
matic cataract and cataract surgery for congenital cataract
were pooled for the analysis. There is a potential possibil-
ity that the vitreous proteome in some cases is influenced
by associated pathology in these subjects. However, this
was close to normal vitreous that we could obtain for the
study.
Known proteins in the vitreous humor
Among the identified proteins in vitreous, we found
many proteins that had been previously described in the
vitreous, confirming the validity of the proteomic approach
undertaken by us. Among the proteins previously reported
in vitreous are aldolase A, fructose-bisphosphate (ALDOA),
cystatin C (CST3), dickkopf homolog 3 (DKK3), orosomu-
coid 2 (ORM2), serpin peptidase inhibitor, clade C member
1 (SERPINC1), insulin-like growth factor binding protein 7
(IGFBP7), lipocalin 2 (LCN2), TIMP metallopeptidase in-
hibitor 2 (TIMP2), C-type lectin domain family 3, member
B (CLEC3B), lectin mannose-binding 2 (LMAN2), opticin
(OPTC), serpin peptidase inhibitor clade F (SERPINF1).
Representative MS/MS spectra of some identified proteins
in this study are shown in (Figure 2).
We identified several components of complement
system including complement C1q subcomponent subunit
A (C1QA), C1QB, C1QC, C1QL3, C1QTNF3, C1QTNF5,
Figure 1 Experimental design for proteomic characterization of vitreous humor. Pooled vitreous humor samples were depleted of
abundant proteins using Agilent’s MARS 14 column followed by in-gel digestion, in-solution digestion and OFFGEL electrophoresis. The samples
were analyzed on LTQ-Orbitrap Velos mass spectrometer.
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C8A, C8B, C8G, C9, CFB, CFD, CFH, CFHR1, CFHR2,
CFHR3, CFI.
Activation of the complement pathways can initiate
and accelerate thrombosis, apoptosis and leukostasis, all
of which could be important steps in the development of
diabetic retinopathy [20]. Some of the complement factorsare also associated with age-related macular degeneration
(AMD). Raychaudhuri et al., have shown that compro-
mised complement factor H (CFH) function contributes
to pathogenesis of AMD [21]. CFH risk allele reveals a
polymorphism representing a tyrosine to histidine change
at amino acid 402, which is associated with AMD [22].
This region of CFH is crucial for binding of heparin and
Table 1 A partial list of novel proteins identified in this study
Gene symbol Description Cellular component Biological process Molecular function
LCN1 Lipocalin-1 Extracellular Transport Transporter activity
TIMP1 Metalloproteinase inhibitor 1 Extracellular Cell growth Extracellular matrix structural constituent
SPARC Sparc Extracellular Cell growth and/or maintenance Extracellular matrix structural constituent
CHRDL1 Chordin-like protein 1 Unknown Cell communication,
Signal transduction
Molecular function unknown
DCD Dermcidin Extracellular Immune response Molecular function unknown
C19orf10 Hypothetical protein loc56005 Unknown Cell communication,
Signal transduction
Growth factor activity
PI3 Elafin Extracellular Protein metabolism Protease inhibitor activity













FLG Filaggrin Nucleus Cell communication,
Signal transduction
Calcium ion binding
ACTB Actin, cytoplasmic 1 Cytoplasm Cell growth and/or maintenance Structural constituent of cytoskeleton
AZU1 Azurocidin Cytoplasmic vesicle Immune response Defense/immunity protein activity
NENF Neudesin Extracellular Biological_process unknown Kinase regulator activity
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SNP in complement factor 1 is associated with risk of
AMD [24].
Opticin (OPTC) is a member of the small leucine-rich
repeat protein (SLRP) family. Opticin is expressed in the
retina, skin, iris, vitreous humor, non-pigmented epi-
thelium of the ciliary body, sclera, optic nerve, choroid,
corneal epithelium, uveal tract and lens [25-27]. It is
associated with age related macular degeneration and
posterior column ataxia with retinitis pigmentosa, both
of which are inherited eye diseases [28].
Retinol-binding protein 3 (RBP3) is a soluble single
subunit glycoprotein that is synthesized and secreted byTable 2 A summary of some of the previously published prot
mass spectrometry platforms
Study Fractionation/separation method
1. Aretz S et al., [16] SDS-PAGE, Liquid phase IEF
2. Simo et al., [17] DIGE, Western blot
3. Gao et al. [14] SDS-PAGE
4. Kim et al. [13] 2-DE
SDS-PAGE
5. Ouchi et al. [15] 2D-PAGE
6. Wu et al., [18] SDS-PAGE
7. Yamane et al., [19] 2D-PAGE
8. Nakanishi et al. [12] 2D-PAGErod photoreceptor cells into the interphotoreceptor matrix
[29-32]. It is believed to transport all trans retinol to the
retinal pigment epithelium (RPE) and 11-cis retinal from
the RPE to the bleached photoreceptors, thus playing an
important role in the visual cycle [33]. A mutation in the
RBP3 gene (Asp1080Asn) has been linked to autosomal
recessive retinitis pigmentosa [34]. RBP3 is known to
modulate the notch signal transduction by interacting
with the phosphorylated intracellular domain of the
notch receptor [35]. It is surprising that molecules
such as RBP3, which appears to function at the back of
the retina farthest from the vitreous, could still be
found in the vitreous. The possible explanation for thiseomics studies on vitreous humor and the corresponding











Figure 2 Representative MS/MS spectra of known proteins in vitreous that were identified in this study. A. peptide YLAEFATGNDR
belongs to 14-3-3 protein epsilon. B. Peptide EVPDEYEVGSFMEEVR belongs to dickkopf-related protein 3. C. Peptide TFHEASEDCISR belongs to tet-
ranectin. D. Peptide IDLSNNLISSIDNDAFR belongs to opticin.
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are prevented from directly reaching the vitreous by the
presence of the blood ocular barrier, there is no evidence
of an effective barrier for proteins in the intercellular and
interstitial spaces of retina and surrounding tissues.
Serpin peptidase inhibitor, clade F, member 1 (SERPINF1)
is a 50 kDa secreted glycoprotein and reported to be
expressed in many tissue and vitreous [36,37]. It belongs
to a group of serine protease inhibitors with anti-
angiogenic activities [38,39]. SERPINF1 concentration is
found to be significantly lower in the vitreous fluid of
subjects with PDR [40-42].
Novel proteins identified in the vitreous humor
Representative MS/MS spectra of two unique proteins
identified in this study –Interleukin 6 (IL-6) and transform-
ing growth factor beta-2 (TGFB2) are shown in Figure 3.
Interleukin-6 is a cytokine released in acute and chronic
inflammation. This molecule has been extensively studied
as an early indicator of inflammatory disorders such as
acute pancreatitis and urticaria [43,44]. All insulin-like
growth factor-binding proteins (IGFBP) are secreted and
have a leader sequence. They are conserved at amino and
carboxyl terminal with 18 cysteine residues. All these
genes encode proteins with an IGFBP domain and a
thyroglobulin type-I domain. These proteins bind to
insulin-like growth factors (IGFs) I and II and arefound in the plasma in the form of glycosylated and
non-glycosylated forms [45-48]. IGFBP4, IGFBP6 are
O-glycosylated and IGFBP5 and IGFBP6 are N-glycosylated
[49,50]. IGFBP6 is tumor suppressor, [51] extracellular pro-
tein [52] and preferentially binds to IGF-II [53]. IGFBP2
serves as an antiapoptotic biomarker [54]. We identified
several members of the insulin-like growth factor-binding
protein (IGFBP) family including IGFBP2, IGFBP4, insulin-
like growth factor 2 (IGF2), insulin-like growth factor
binding protein acid labile subunit (IGFALS). Other
members of this family, IGFBP5, IGFBP6 and IGFBP7,
have already been identified in previous studies.
We compared our results with other high throughput
studies on vitreous humour [13,14,16]. We have identified
523 proteins identified by other studies. In addition,
we have identified 682 novel proteins not described in
previous studies. Of the 682 novel proteins, we identified
proteins such as S-Arrestin(SAG) and transforming growth
factor-beta 2 (TGF-B2) which are involved in the patho-
physiology of ocular diseases. S Arrestin, also known as S
antigen(S-Ag) is a major photoreceptor protein. It is a
member of the beta-arrestin protein family which partici-
pate in agonist-mediated desensitization of G-protein-
coupled receptors. Arrestin preferentially binds light
activated phosphorylated rhodopsin and prevents fur-
ther signaling by direct competition with transducin, a
visual G-protein [55]. It is expressed in the retina and
Figure 3 Representative MS/MS spectra of novel proteins identified in this study. A. Peptide FAGIDGTSTYTSGDQK belongs to Transforming
growth factor beta-2 (TGFB2). B. Peptide YILDGISALR belongs to Interleukin-6 Precursor (IL-6).
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been implicated in experimental uveoretinitis. There is
also recent evidence to suggest S-Ag specific T cells may
be involved in the pathophysiology of Bechets disease, a
chronic, relapsing, multisystem inflammatory disorder
characterized by recurrent oral and genital ulcers, severe
intraocular inflammation and skin lesions [56]. Mutations
in the S Arrestin gene is also associated with an autosomal
recessive form of night blindness known as Oguchi disease
[57-59].
Transforming growth factor-beta 2(TGF-B2) belongs
to the TGFB family of cytokines. These proteins bind to
their transmembrane receptors, which in turn activatetheir downstream effectors like SMAD proteins which
are known to regulate cell proliferation, apoptosis and
differentiation [60]. Primary open angle glaucoma is a
disease of the eye which is characterized by elevated intra
ocular pressure due to increased resistance to the outflow
of aqueous humor through the trabecular meshwork.
TGF-B2 has been shown to be elevated in the aqueous
humor of patients with primary open angle glaucoma. Its
role in glaucoma is thought to be due to the increased
production of extracellular matrix in the trabecular
meshwork [61]. A genetic defect in the gene that codes
for this protein is associated with Peter's anomaly which is
a congenital defect of the anterior chamber of the eye [62].
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We carried out a bioinformatics analysis of subcellular
localization, molecular function and biological pro-
cesses by searching the identified proteins against the
manually curated Human Protein Reference Database
(HPRD; http://hprd.org) and Human Proteinpedia (http://
humanproteinpedia.org) [63-65]. Of the 1,205 proteins
identified in this study, 599 proteins possess signal pep-
tides and 318 proteins are reported to be localized in
extracellular compartment. As illustrated in Figure 4A,
the majority of the proteins reported in our study were
localized to extracellular space (24%), cytoplasm (20%)
or plasma membrane (14%). We also classified proteins
based on molecular functions and biological processes
as shown in Figure 4B, C. Classification based on mo-
lecular function showed that the large majority of the
proteins are involved in catalytic activity (27%), struc-
tural activity (10%), binding activity such as calcium
ion binding, receptor binding and complement binding
(10%), cell adhesion molecule activity (4%), and trans-
porter activity (4%). A large group (19%) of proteins
are still unclassified in terms of their molecular func-
tion. Further categorization was done for biological
processes which constitute metabolism (28%), cell
communication (19%), cell growth (12%), and immune
response (7%).Figure 4 Subcellular localization and functional annotation of protein
subcellular localization of identified proteins. B. Molecular functions of iden
data regarding proteins was obtained from Human Protein Reference DataConclusions
Our study provides a comprehensive proteomics profile
of the human vitreous humor. Many of the pathologic
changes occurring in the retina are likely to be reflected
in the vitreous because of its close proximity to the retina
and also because of the breakdown of the blood retinal
barrier. Hence, a proteomic study of the vitreous in related
retinal diseases such as diabetic retinopathy, retinal de-
tachment and central or branch retinal vein occlusions
would provide valuable insights about the pathophysiology
of these diseases. The information from our study could
serve as a baseline for future studies especially those
aimed at identifying biomarkers for retinal disorders.
Materials & methods
Vitreous sample collection
The vitreous samples for the proteomic analysis were
obtained from five patients undergoing vitrectomy for
macular hole, three patients with congenital cataract
who underwent cataract surgery with intra-ocular lens
implantation and primary posterior capsulotomy and
two samples from patients with traumatic cataract with
undisturbed vitreous and intact lens capsule but who
also needed vitreous surgery due to zonular damage.
All samples were collected by pars plana vitrectomy,
were centrifuged at 13,000 rpm at 4°C for 15 minutes ands identified in vitreous humor. A. Gene Ontology analysis for
tified proteins. C. Biological processes of the identified proteins. The
base (HPRD: http://www.hprd.org).
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obtained from all the subjects and the research adhered
to the tenets of Declaration of Helsinki. The study was
approved by the Ethics committee “Science for Health”
under the approval number 20080713/SFH-014/010.
Pooled samples were concentrated by 3 kDa filter through
low-adsorption membranes (Amicon, Milliore, Billerica,
MA). Protein estimation was carried out for pooled concen-
trated sample using Lowry’s assay (BioRad Laboratories). A
total of 4 mg protein was subjected to Agilent’s Multiple
Affinity Removal System 14 (MARS 14) for depletion of
abundant proteins. MARS 14 column is routinely used for
depletion of abundant proteins in serum/plasma. This step
allows us to deplete highly abundant albumin, IgG, trans-
ferrin, heptoglobin, IgM, IgA, fibrinogen, alpha antitryp-
sin, apolipoprotein A1, alpha 1 acid glycoprotein, alpha2
macroglobin, transthyretin, complement C3 and apolipo-
proteins. We had to optimize our procedures for depletion
of abundant proteins from vitreous humor. For each de-
pletion cycle, Agilent recommends 20 μl of serum that is
approximately equivalent to 1 mg of total protein. During
depletion of abundant proteins from vitreous, we also
used 1 mg of protein for each depletion cycle. As we had
4 mg protein, we carried out 4 independent depletion cy-
cles and pooled the flow through fractions. After passing
the vitreous sample through MARS 14 column, 460 μg of
protein was recovered in the flow through and the
remaining 3.54 mg of protein accounted for the bound
fraction. 60 μg of depleted vitreous sample was resolved
on SDS-PAGE and subjected to in-gel digestion prior to
mass spectrometry analysis. The remaining 400 μg of pro-
tein was reduced (5 mM DTT), alkylated (20 mM iodoa-
cetamide) and digested using trypsin 1:20 w/w (Promega,
Madison, WI) overnight at 37°C. The samples were acid-
ified by adding 20% trifluoro acetic acid (TFA) to a final
concentration of 0.1% and desalted using C18 macro-spin
columns (Harvard apparatus, catalog no. 74-4101). 200 μg
peptide digest was used for SCX fractionation as well as
OFFGEL fractionation.
In-gel digestion
Sixty micrograms of depleted vitreous sample was resolved
by SDS-PAGE and stained using colloidal Coomassie
stain. The lane was excised into 16 pieces and destained
with 40 mM ammonium bicarbonate in 50% acetonitrile
(ACN). Trypsin digestion was carried out essentially as de-
scribed previously [66,67]. Briefly, reduction was carried
out using 5 mM dithiothreitol (DTT, 60°C for 45 minutes)
followed by alkylation using 20 mM iodoacetamide (room
temperature for 10 min). Sequencing grade modified por-
cine trypsin (Promega, Madison, WI, US) in ammonium
bicarbonate was added to the gel pieces at 4°C and incu-
bated for 45 minutes. Excess trypsin was removed and the
gel pieces were immersed in ammonium bicarbonate andincubated overnight at 37°C. The peptides were extracted
from the gel bands using 0.4% formic acid in 3% ACN
twice, once using 0.4% formic acid in 50% ACN and once
using 100% ACN. The extracted peptides were dried using
speedvac and stored at -80°C until LC-MS/MS analysis.
Strong cation exchange chromatography
The peptide digest equivalent to 200 μg was reconstituted
with 10 mM potassium phosphate buffer containing 30%
ACN, pH 2.7 (solvent A). SCX fractionation was carried
out using Polysulfoethyl A column (PolyLC, Columbia,
MD) (300 Å, 5 μm, 100 × 2.1 mm) using an Agilent 1200
HPLC system (Agilent Technologies, Santa Clara, USA)
containing a binary pump, UV detector and a fraction col-
lector [68,69]. The peptides were eluted using a linear salt
gradient (0 to 35%) of solvent B (10 mM potassium phos-
phate buffer containing 30% ACN, 350 mM KCl, pH 2.7)
at a flow rate of 200 μl/min. The fractions were com-
pletely dried and reconstituted in 0.1% TFA. They were
desalted using stage-tips and dried on speedvac.
OFFGEL fractionation
The peptide digest equivalent to 200 μg in-solution digest
was used for OFFGEL fractionation [70,71]. Agilent 3100
OFFGEL fractionator (Agilent Technologies, Santa Clara,
USA) was used for pI based separation of peptides. As per
the protocol, peptides were separated using pH 3-10
Immobilized pH gradient (IPG) strip, 13 cm. The peptides
were focused at 50 kVh with maximum current of 50 μA
and maximum voltage set to 4000 V. Twelve fractions
were collected and acidified to obtain a final concentration
of 0.1% TFA prior to sample cleaning using stage-tip
protocol [72].
LC-MS/MS analysis
LC-MS/MS analyses of the samples were carried out using
high resolution Fourier transform mass spectrometer, LTQ-
Orbitrap Velos (Thermo Electron, Bremen, Germany). The
mass spectrometer was interfaced with a nano-LC system
to a trap column (2 cm× 75 μm, C18 material 5 μm,
120 Å) and an analytical column (10 cm× 75 μm, C18 ma-
terial 5 μm, 120 Å). Electrospray source was fitted with an
8 μm emitter tip (New Objective, Woburn, MA) and was
applied a voltage of 2000 V. Peptide samples were loaded
onto trap column in 3% solvent B (90% ACN in 0.1% for-
mic acid) and washed for 5 minutes before peptide elution
using a gradient of 3-35% solvent B for 60 minutes at a
constant flow rate of 0.4 μl/min. Xcalibur 2.1 (Thermo
Electron, Bremen, Germany) was used for data acquisi-
tion. The MS spectra were acquired in a data-dependent
manner targeting the twenty most abundant ions in each
survey scan in the range of m/z 350 to 1,800. Precursor
ions selected for MS/MS fragmentation were dynamically
excluded for 30s. Target ion quantity for FT full MS and
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collisional dissociation (HCD) was used for precursor
fragmentation. MS and MS/MS data were acquired at a
resolution of 60,000 and 15,000 at 400 m/z, respectively.
Internal calibration was enabled using polydimethylcyclo-
siloxane (m/z, 445.1200025) ions and lock mass was used
for accurate mass measurements.
Data analysis
Mass spectrometry data was processed using the Prote-
ome Discoverer software (Version 1.4.1.14, Thermo Fisher
Scientific, Bremen, Germany). Mascot, SEQUEST and X!
Tandem search engines were employed to maximize the
peptide identification. The mass spectrometry data was
searched against NCBI RefSeq 59 human protein database
containing 36,211 sequences with known contaminants.
Carbamidomethylation of cysteine was used as the fixed
modification and oxidation of methionine and protein
N-terminal acetylation as variable modifications. Peptide
mass and fragment mass tolerance were set as 20 ppm
and 0.1 Da, respectively with 1 missed cleavage. Peptide
identifications were filtered by setting 1% target false dis-
covery rate (FDR). Subcellular localization, molecular
function and biological process of identified proteins were
analyzed using gene ontology (GO) compliant databases -
Human Protein Reference Database (HPRD: http://www.
hprd.org) and Human Proteinpedia [63,73].
Data availability
The raw data obtained from vitreous proteome are submit-
ted to public data repositories. The peptide identifications
and MS/MS spectra are available on Human Proteinpedia
[63], (https://www.humanproteinpedia.org) as accession
number HuPA_00682. The mass spectrometry proteo-
mics data have been deposited to the ProteomeXchange
Consortium [74] via the PRIDE partner repository with
the dataset identifier PXD000957.
Additional files
Additional file 1: Table S1. A complete list of proteins identified in the
vitreous humor. This table provides a list of all the proteins identified in
vitreous including their gene symbol, RefSeq accession, protein
description, number of peptides, sequence coverage, reported subcellular
localization, molecular function, biological process and domains/motifs.
Additional file 2: Table S2. A list of all peptides identified in the
vitreous humor.
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